14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OBIO vs BOLD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (36.8/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality), while OBIO wins 4–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (41.1/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both OBIO (41.1/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OBIO vs BOLD. Trailing 12-month operating profitability (OBIO -195.4% vs BOLD 0.0%) and valuation multiples (OBIO N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ OBIO vs BOLD Key Questions & Quantitative Answers
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (36.8/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality), while OBIO wins 4–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (41.1/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY). Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both OBIO (41.1/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, OBIO generates $31M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.
OBIO screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus BOLD (-64.6% ROE) capital efficiency.
In options market volatility and institutional positioning, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.